Cat.#: ASSD-222
| Description | Antifade Fluorescence Mounting Medium from Ace Therapeutics with propidium iodide (hardset) is used to prevent the photobleaching of fluorescent proteins and dyes during fluorescent imaging. This product contains propidium iodide which is a widely used red-fluorescent intercalating agent that binds and labels nucleic acids. |
| Size | 10 mL |
| Applications | Cellular imaging, IHC(IF), ICC |
| Mounting | Aqueous (hardset) - cures in approximately 1 hour at room temperature |
| Antifade | Yes |
| Counterstain | Propidium Iodide |
| Refractive index | ≈1.45 (initial) which then increases to ≈1.518 once cured |
| Emission color | Red |
| Excitation | 535 nm |
| Emission | 617 nm |
| Closest laser lines | 532 nm |
| Cell permeable | Yes |
| Storage | +4°C or -20°C long-term. |
| Shipping | Shipped at 4°C |
| Important | If the mounting medium solidifies prematurely during operation, simply heat the bottle to approximately 60°C and the mounting medium will reliquefy. We strongly recommend storing this product in a storage buffer containing 0.05% sodium azide and away from light. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-194 | 7-(Diethylamino)coumarin-3-carboxylic acid (AC194) | 100 mg | inquiry |
| ASSD-205 | Acridinium C2 NHS Ester (AC205) | 5 mg, 10 mg | inquiry |
| ASSD-218 | 6-Carboxy-2′,7′-dichlorofluorescein-3′,6′-diacetatesuccinimidyl Ester (AC218) | 25 mg | inquiry |
| ASSD-221 | Antifade Fluorescence Mounting Medium with DAPI (hard set) (AC221) | 10 mL | inquiry |
| ASSD-199 | 4,7-Dioxaoctylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[2-fluoro-4′-phosphophenylacetic Acid] Diamide (AC199) | 500 μg | inquiry |
| ASSD-135 | JC-1 (AC135) | 5 mg | inquiry |
| ASSD-111 | Propidium Iodide (AC111) | 10 mg, 50 mg | inquiry |
| ASSD-121 | Fluorescent adenosine A3 antagonist [XAC] (AC121) | 500 μg | inquiry |
| ASSD-217 | t-Boc-MTSEA-Fluorescein (AC217) | 10 mg | inquiry |
| ASSD-102 | DAPI (AC102) | 10 mg, 50 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.